HGSI Said LymphoStat-B Drug Did Not Meet the Overall Primary Efficacy Endpoints
Tweet Send to a Friend
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the results of a Phase 2 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
